Repare Therapeutics Inc. (RPTX)

Market Cap	91.13M
Revenue (ttm)	11.87M
Net Income (ttm)	-72.20M
Shares Out	42.99M
EPS (ttm)	-1.69
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	497,266
Open	2.120
Previous Close	2.110
Day's Range	2.110 - 2.140
52-Week Range	0.890 - 4.070
Beta	1.04
Analysts	Strong Buy
Price Target	3.50 (+65.09%)
Earnings Date	Nov 14, 2025

About RPTX

Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics in Switzerland and the United States. The company uses its proprietary, genome-wide and CRISPR-enabled SNIPRx platform to discover and develop cancer therapies that treat cancers due to mechanisms of genomic instability, including DNA damage repair. It also develops camonsertib (RP-3500), a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and Rad3-related protein kinase that is in Phase 1/2 c...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 19, 2020
• Employees: 129
• Stock Exchange: NASDAQ
• Ticker Symbol: RPTX
• Website: https://www.reparerx.com

Financial Performance

In 2024, Repare Therapeutics's revenue was $53.48 million, an increase of 4.58% compared to the previous year's $51.13 million. Losses were -$84.69 million, -9.71% less than in 2023.

Analyst Summary

According to 3 analysts, the average rating for RPTX stock is "Strong Buy." The 12-month stock price target is $3.5, which is an increase of 65.09% from the latest price.

Price Target

$3.5

(65.09% upside)

Analyst Consensus: Strong Buy